Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | GLI1 | P08151 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL2588288 | 0.86 | TLR2 (0.30) | TLR2 | |
| SCHEMBL51271 | 0.86 | NOS2 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL2537702 | 0.85 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL3489282 | 0.85 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL7536202 | 0.85 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL11858950 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL756555 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL1537227 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| Serine SCHEMBL17199761 | 0.84 | ALOX15 (0.41) | NOS2NOS3NOS1 | |
| SCHEMBL787736 | 0.82 | DPP7 (0.35) | NOS2NOS3NOS1PRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197952-A | Mutant gene of rice waxy gene Wx and application thereof | 重庆市农业科学院 | 2022-10-18 | — | — | CN | claimed |
| EP-2528581-B1 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | AMBROSIALAB S R L (IT) | 2019-11-06 | — | — | EP | claimed |
| CN-108771168-A | A kind of cucumber peel preparation method | 广西博白县众旺农产品专业合作社 | 2018-11-09 | — | — | CN | claimed |
| EP-2528581-A2 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | Ambrosialab S.r.L. (IT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092581-A2 | METHOD AND COMPOSITIONS FOR THE APPLICATION OF AMINO ACIDS ON THE SKIN THROUGH AN ANHYDROUS MEAN | AMBROSIALAB S.R.L. (IT) | 2011-08-04 | — | — | WO | claimed |
| US-20110178000-A1 | Apoptotically Active Peptides | CYTOTOOLS AG (DE) | 2011-07-21 | — | — | US | claimed |
| US-5905142-A | Protease resistant PDGF and methods of use | ZYMOGENETICS, INC. (US) | 1999-05-18 | — | — | US | claimed |
| US-20240139259-A1 | ENZYME AND PROBIOTICS TAKEN WITH PROTEIN, CREATE A WHOLISTIC SYSTEM THAT PREVENTS THE NEGATIVE EFFECTS OF PROTEIN INDIGESTION ON GUT MICROBIOTA, PROMOTE MICROFLORA BALANCE, AND INCREASE THE BIOAVAILABILITY OF POSTBIOTICS | ADVANCED ENZYME TECHNOLOGIES LTD. (IN) | 2024-05-02 | — | — | US | disclosed |
| WO-2024079433-A1 | PMHC-BINDING HETERODIMERIC RECEPTORS WITH AN IMPROVED DISCRIMINATION BETWEEN A LOW AFFINITY AND A HIGH AFFINITY PMHC AND THAT DO NOT ASSOCIATED WITH CD3 | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-04-18 | — | — | WO | disclosed |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-113166034-B | Diester compounds as pro-fragrances | 长谷川香料株式会社 | 2023-08-15 | — | — | CN | disclosed |
| US-11596695-B2 | Specific sites for modifying antibodies to make immunoconjugates | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| CN-115197952-A | Mutant gene of rice waxy gene Wx and application thereof | 重庆市农业科学院 | 2022-10-18 | — | — | CN | disclosed |
| EP-1541169-A1 | Use of limk-1, its analogues and ligands for the production of a medicament against a thrombus formation of blood clotting disease | Aventis Pharma Deutschland GmbH (DE) | 2005-06-15 | — | — | EP | disclosed |
| CN-1468317-A | Use of multiple recombination sites with unique specificity in recombinant cloning | ά | 2004-01-14 | — | — | CN | disclosed |
| US-20030215833-A1 | Variant cleavage stimulation factor and its encoding nucleic acid | TEXAS TECH UNIVERSITY | 2003-11-20 | — | — | US | disclosed |
| WO-2001011065-A2 | HEPATITIS A VIRUS CLONES ADAPTED FOR GROWTH IN AGMK CELLS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-15 | — | — | WO | disclosed |
| EP-0576669-A4 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORP (US) | 1996-05-08 | — | — | EP | disclosed |
| EP-0576669-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1993013794-A1 | NOVEL METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISEASES | REPLIGEN CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | NOS2 4527/4885NOS3 4571/4885NOS1 4769/4885 |
| US-11596695-B2 | Specific sites for modifying antibodies to make immunoconjugates | PTMS, FCGR2A, FCGR3B | NOS2 4527/4885NOS3 4571/4885NOS1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.